Back to mobile site
Get it on Google Play

Lantern Pharma gets Taiwan approval for next phase of LP-300 trial

October 7, 2026 8:31 AM EDT Send to a Friend
Lantern Pharma Inc. (NASDAQ: LTRN) announced it has received regulatory and institutional review board approvals in Taiwan to open Part ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login